{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:18:39Z","timestamp":1793056719363,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007923","name":"University of Wisconsin Carbone Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jtct.2023.11.014","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T14:50:59Z","timestamp":1699973459000},"page":"191-202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy"],"prefix":"10.1016","volume":"30","author":[{"given":"Ameet K.","family":"Mishra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella B.","family":"Martell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex S.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyna E.","family":"Dogru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiman","family":"Hematti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Callander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.11.014_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.11.014_bib0003","first-page":"163","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharmaceut Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0004","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2023.11.014_bib0005","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.11.014_bib0006","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2023.11.014_bib0007","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.jtct.2023.11.014_bib0008","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2023.11.014_bib0009","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0010","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11:eaau7746","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-019-0178-8","article-title":"Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma","volume":"9","author":"Stewart","year":"2019","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.jtct.2023.11.014_bib0012","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.11.014_bib0013","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41408-020-00405-z","article-title":"Preclinical development of CD126 CAR-T cells with broad antitumor activity","volume":"11","author":"Mishra","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2023.11.014_bib0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138(suppl 1)","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.014_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cyto.a.24350","article-title":"Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre","volume":"101","author":"Ashhurst","year":"2022","journal-title":"Cytometry A"},{"key":"10.1016\/j.jtct.2023.11.014_bib0016","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood-2002-02-0657","article-title":"Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1)","volume":"100","author":"Voehringer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.014_bib0017","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI41264","article-title":"Absence of mouse 2B4 promotes NK cell\u2013mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis","volume":"120","author":"Waggoner","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.11.014_bib0018","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2023.11.014_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jtct.2023.11.014_bib0020","doi-asserted-by":"crossref","first-page":"eabl3642","DOI":"10.1126\/sciimmunol.abl3642","article-title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","volume":"7","author":"Vasic","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jtct.2023.11.014_bib0021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-019-0507-2","article-title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","volume":"7","author":"Yao","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.11.014_bib0022","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13046-019-1126-y","article-title":"Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade","volume":"38","author":"Fang","year":"2019","journal-title":"J Exp Clin Cancer Res."},{"issue":"suppl 1","key":"10.1016\/j.jtct.2023.11.014_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-141505","article-title":"Safety and efficacy of ex vivo expanded healthy donor-derived double negative T cells for the treatment of AML relapsed after allogeneic stem cell transplantation: a first in-human phase I\/IIa clinical trial","volume":"136","author":"Baolin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.014_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40425-016-0164-7","article-title":"Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors","volume":"4","author":"Hall","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.11.014_bib0025","article-title":"Tumor-infiltrating lymphocytes (TILs) from patients with glioma","volume":"6","author":"Liu","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtct.2023.11.014_bib0026","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcmgh.2019.08.004","article-title":"Unique T-cell populations define immune-inflamed hepatocellular carcinoma","volume":"9","author":"Di Blasi","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol."},{"key":"10.1016\/j.jtct.2023.11.014_bib0027","article-title":"Immune cell composition in human non-small cell lung cancer","volume":"9:3101","author":"Stankovic","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.jtct.2023.11.014_bib0028","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0029","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.11.014_bib0031","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0032","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.immuni.2020.09.005","article-title":"Central memory CD8+T cells derive from stem-like Tcf7hi effector cells in the absence of cytotoxic differentiation","volume":"53","author":"Pais Ferreira","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2023.11.014_bib0033","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.4049\/jimmunol.0901199","article-title":"Constitutive activation of Wnt signaling favors generation of memory CD8 T cells","volume":"184","author":"Zhao","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2023.11.014_bib0034","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.immuni.2018.03.015","article-title":"KLRG1+ effector CD8+T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity","volume":"48","author":"Herndler-Brandstetter","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2023.11.014_bib0035","doi-asserted-by":"crossref","first-page":"9571","DOI":"10.1073\/pnas.0503726102","article-title":"Central memory self\/tumor-reactive CD8+T cells confer superior antitumor immunity compared with effector memory T cells","volume":"102","author":"Klebanoff","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtct.2023.11.014_bib0036","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","article-title":"Memory T cell\u2013driven differentiation of naive cells impairs adoptive immunotherapy","volume":"126","author":"Klebanoff","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.11.014_bib0037","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"Berger","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2023.11.014_bib0038","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.11.014_bib0039","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.11.014_bib0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723016810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:11:33Z","timestamp":1763003493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723016810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2666636723016810"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.11.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}